Spotlight: Fusion Genomics

Dr. Poul Sorensen


As part of the annual report, Compute Canada has highlighted some of its users and their projects.

Fusion GenomicsFusion Genomics is a Canadian company that was able to transform its discovery research into a commercial interest. With access to powerful computing resources supported by Compute Canada and WestGrid, a Simon Fraser University-based research lab gained access to commercialize products that are available in the marketplace today.

Fusion Genomics has a number of different research assets for use in cancer and infectious diseases. Its line of innovative, highly sensitive and accurate assets are designed around its Quantum Probe™ technology and can be rapidly developed and configured for a number of applications.

A team led by Dr. Poul Sorensen, Senior Scientist at the BC Cancer Agency and Professor of Pathology and Laboratory Medicine at the University of British Columbia developed the first product: ChildSeqRNA. This is the first diagnostic tool to employ next-generation sequencing (NGS) technology to produce highly sensitive results (at the DNA level) in a fraction the time. Childhood sarcomas are aggressive cancers that affect the bones and soft tissues of children and adolescents.

To read the complete annual report, please visit our online publication.

Leave A Comment